Two drugs for RET-altered cancers (Retevmo and Gavreto)

Med Lett Drugs Ther. 2023 Jul 10;65(1680):e129-e131. doi: 10.58347/tml.2023.1680e.
No abstract available

Keywords: Gavreto; Retevmo; adverse effects; cabozantinib; dosage; drug interactions; efficacy; pralsetinib; safety; selpercatinib; thyroid cancer; vandetanib.

MeSH terms

  • Humans
  • Lung Neoplasms*
  • Neoplasms* / drug therapy
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-ret / genetics
  • Pyrimidines
  • Thyroid Neoplasms*

Substances

  • pralsetinib
  • Pyrimidines
  • Protein Kinase Inhibitors
  • RET protein, human
  • Proto-Oncogene Proteins c-ret